NMS-03305293
Phase 1Small molecule
NMS-03305293 is one of 108 small molecule programs targeting Ovarian Cancer. It is currently in Phase 1.
3
Indications
4
Total Trials
3
Active Trials
107
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Tylenol
KKenvue Brands
Phase 3
Trastuzumab Deruxtecan
AstraZenecaPhase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
AK104
AAkeso
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Masitinib
AAB Science
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NMS-03305293. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNerviano Medical Sciences